NICE backs Novartis' Kymriah in acute lymphoblastic leukemia

U.K.'s NICE recommended in final guidance on Nov. 15 that CAR T therapy Kymriah tisagenlecleucel from Novartis AG (NYSE:NVS;

Read the full 191 word article

User Sign In